P-041 IKAROS: a potential prognostic marker in pancreatic ductal adenocarcinoma

di Cruz Ramos, M., Rodriguez-Remirez, M., Minguez, P., Cebrian, A., del Puerto-Nevado, L., Celdran, A., Garcia-Foncillas Lopez, J.
Pubblicato in Ann Oncol (2016)

The potential predictive value of DEK expression for neoadjuvant chemoradiotherapy response in locally advanced rectal cancer

di Martinez-Useros, J., Moreno, I., Fernandez-Aceñero, M. J., Rodriguez-Remirez, M., Borrero-Palacios, A., Cebrian, A., Gomez del Pulgar, T., del Puerto-Nevado, L., Li, W., Puime-Otin, A., Perez, N., Soengas, M. S., Garcia-Foncillas, J.
Pubblicato in BMC Cancer (2018)

Identification of Poor-outcome Biliopancreatic Carcinoma Patients With Two-marker Signature Based on ATF6α and p-p38 “STARD Compliant”

di Martinez-Useros, J., Georgiev-Hristov, T., Borrero-Palacios, A., Fernandez-Aceñero, M.J., Rodríguez-Remírez, M., del Puerto-Nevado, L., Cebrian, A., Gomez del Pulgar, M.T., Cazorla, A., Vega-Bravo, R., Perez, N., Celdran, A., Garcia-Foncillas, J.
Pubblicato in Medicine (Baltimore) (2015)

Active angiogenesis in metastatic renal cell carcinoma predicts clinical benefit to sunitinib-based therapy

di del Puerto-Nevado, L, Rojo, F, Zazo, S, Caramés, C, Rubio, G, Vega, R, Chamizo, C, Casado, V, Martínez-Useros, J, Rincón, R, Rodríguez-Remírez, M, Borrero-Palacios, A, Cristóbal, I, Madoz-Gúrpide, J, Aguilera, O, García-Foncillas, J
Pubblicazione 2014

Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

di Borrero-Palacios, A., Cebrián, A., Gómez del Pulgar, M. T., García-Carbonero, R., Garcia-Alfonso, P., Aranda, E., Elez, E., López-López, R., Cervantes, A., Valladares, M., Nadal, C., Viéitez, J. M., Guillén-Ponce, C., Rodríguez, J., Hernández, I., García, J. L., Vega-Bravo, R., Puime-Otin, A., Martínez-Useros, J., Del Puerto-Nevado, L., Rincón, R., Rodríguez-Remírez, M., Rojo, F., García-Foncillas, J.
Pubblicato in Sci Rep (2019)

Author Correction: Combination of KIR2DS4 and FcγRIIa polymorphisms predicts the response to cetuximab in KRAS mutant metastatic colorectal cancer

di Borrero-Palacios, A., Cebrián, A., Gómez del Pulgar, M. T., García-Carbonero, R., Garcia-Alfonso, P., Aranda, E., Elez, E., López-López, R., Cervantes, A., Valladares, M., Nadal, C., Viéitez, J. M., Guillén-Ponce, C., Rodríguez, J., Hernández, I., García, J. L., Vega-Bravo, R., Puime-Otin, A., Martínez-Useros, J., Del Puerto-Nevado, L., Rincón, R., Rodríguez-Remírez, M., Rojo, F., García-Foncillas, J.
Pubblicato in Sci Rep (2019)